undamentalytics Newsletter
Sign in

Metagenomi Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Metagenomi Therapeutics, Inc. had total assets of $221m, total liabilities of $62.5m and shareholders' equity of $159m. It held $41.7m in cash against $0 of debt: net cash of $41.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMMar 2026
Cash and equivalents141274225
Receivables2100
Total current assets278258166145
Total assets365325221197
Accounts payable2112
Deferred revenue (current)482399
Total current liabilities69372322
Total debt0000
Total liabilities150906359
Shareholders' equity−136235159138
Non-controlling interests and other (assets − liabilities − equity)351———
Net debt (negative = net cash)−141−27−42−25
Shares outstanding34m37m38m38m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: JANX vs MGXCRSP vs MGXABEO vs MGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Metagenomi Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Metagenomi Therapeutics, Inc.